Inhibrx Biosciences (INBX) Depreciation & Amortization (CF) (2023 - 2025)
Inhibrx Biosciences' (INBX) quarterly Depreciation & Amortization (CF) came in at $564000.0 in Q4 2025, down 18.14% year-on-year from $689000.0 in Q4 2024, and down 3.09% on a QoQ basis from $582000.0 in Q3 2025.
Inhibrx Biosciences (INBX) Depreciation & Amortization (CF) (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Depreciation & Amortization (CF) data on file, last reported at $564000.0 in Q4 2025.
- On a quarterly basis, Depreciation & Amortization (CF) fell 18.14% year-over-year to $564000.0 in Q4 2025; TTM through Dec 2025 was $2.5 million, a 8.71% increase from a year earlier, with the FY2025 full-year figure at $2.5 million, up 8.67% from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 stood at $564000.0, down from $582000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for INBX reached as high as $760000.0 in Q3 2024 and fell as low as $295000.0 in Q2 2023.
- Historically, Depreciation & Amortization (CF) has averaged $514909.1 across 3 years, with a median of $564000.0 in 2025.
- Across the five-year window, Depreciation & Amortization (CF) soared 150.0% in 2024 and dropped 23.42% in 2025, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $298000.0 in 2023, then soared by 131.21% to $689000.0 in 2024, then retreated by 18.14% to $564000.0 in 2025.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $564000.0 in Q4 2025, $582000.0 in Q3 2025, and $662000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - | 564,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 564,000.00 |
| Dec 31, 2025 | 564,000.00 |
| Sep 30, 2025 | 582,000.00 |
| Sep 30, 2025 | 582,000.00 |
| Jun 30, 2025 | 662,000.00 |
| Jun 30, 2025 | 662,000.00 |
| Mar 31, 2025 | 675,000.00 |
| Mar 31, 2025 | 675,000.00 |
| Dec 31, 2024 | 689,000.00 |
| Dec 31, 2024 | 689,000.00 |
| Sep 30, 2024 | 760,000.00 |
| Sep 30, 2024 | 760,000.00 |
| Jun 30, 2024 | 475,000.00 |
| Jun 30, 2024 | 475,000.00 |
| Mar 31, 2024 | 360,000.00 |
| Mar 31, 2024 | 360,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Sep 30, 2023 | 304,000.00 |
| Sep 30, 2023 | 304,000.00 |